Published in Arterioscler Thromb Vasc Biol on November 01, 2000
Effects of 5' regulatory-region polymorphisms on paraoxonase-gene (PON1) expression. Am J Hum Genet (2001) 1.85
Determination of paraoxonase 1 status without the use of toxic organophosphate substrates. Circ Cardiovasc Genet (2008) 1.76
Quantification of HDL particle concentration by calibrated ion mobility analysis. Clin Chem (2014) 1.65
Racial differences in paraoxonase-1 (PON1): a factor in the health of southerners? Environ Health Perspect (2009) 1.53
Pharmacogenetics of paraoxonases: a brief review. Naunyn Schmiedebergs Arch Pharmacol (2003) 1.50
Relation between methylmercury exposure and plasma paraoxonase activity in inuit adults from Nunavik. Environ Health Perspect (2011) 1.48
Paraoxonase-1 promoter haplotypes and serum paraoxonase: a predominant role for polymorphic position - 107, implicating the Sp1 transcription factor. Biochem J (2003) 1.30
Engineered recombinant human paraoxonase 1 (rHuPON1) purified from Escherichia coli protects against organophosphate poisoning. Proc Natl Acad Sci U S A (2008) 1.24
Paraoxonase 1 (PON1) status and substrate hydrolysis. Toxicol Appl Pharmacol (2008) 1.21
Pharmacological and dietary modulators of paraoxonase 1 (PON1) activity and expression: the hunt goes on. Biochem Pharmacol (2010) 1.14
Developmental changes in PON1 enzyme activity in young children and effects of PON1 polymorphisms. Environ Health Perspect (2009) 1.13
Validation of PON1 enzyme activity assays for longitudinal studies. Clin Chim Acta (2008) 1.12
Association between the severity of angiographic coronary artery disease and paraoxonase gene polymorphisms in the National Heart, Lung, and Blood Institute-sponsored Women's Ischemia Syndrome Evaluation (WISE) study. Am J Hum Genet (2002) 1.10
Diet, genetics, and disease: a focus on the middle East and north Africa region. J Nutr Metab (2012) 1.10
Human PON1, a biomarker of risk of disease and exposure. Chem Biol Interact (2010) 1.09
The roles of PON1 and PON2 in cardiovascular disease and innate immunity. Curr Opin Lipidol (2009) 1.00
Paraoxonase 1 status as a risk factor for disease or exposure. Adv Exp Med Biol (2010) 0.99
Paraoxonase 1 (PON1) as a genetic determinant of susceptibility to organophosphate toxicity. Toxicology (2012) 0.99
A common mutation in paraoxonase-2 results in impaired lactonase activity. J Biol Chem (2009) 0.97
Paraoxonase 1 (PON1) polymorphisms, haplotypes and activity in predicting cad risk in North-West Indian Punjabis. PLoS One (2011) 0.95
The human paraoxonase gene cluster as a target in the treatment of atherosclerosis. Antioxid Redox Signal (2011) 0.95
TagSNP evaluation for the association of 42 inflammation loci and vascular disease: evidence of IL6, FGB, ALOX5, NFKBIA, and IL4R loci effects. Hum Genet (2006) 0.95
Lead exposure is associated with decreased serum paraoxonase 1 (PON1) activity and genotypes. Environ Health Perspect (2006) 0.94
Paraoxonase 1 polymorphisms and ischemic stroke risk: A systematic review and meta-analysis. Genet Med (2010) 0.94
Novel gene-by-environment interactions: APOB and NPC1L1 variants affect the relationship between dietary and total plasma cholesterol. J Lipid Res (2013) 0.94
Both paraoxonase-1 genotype and activity do not predict the risk of future coronary artery disease; the EPIC-Norfolk Prospective Population Study. PLoS One (2009) 0.93
Genetic variation in LPAL2, LPA, and PLG predicts plasma lipoprotein(a) level and carotid artery disease risk. Stroke (2010) 0.92
Linkage and association of phospholipid transfer protein activity to LASS4. J Lipid Res (2011) 0.91
Pharmacogenetics of paraoxonase activity: elucidating the role of high-density lipoprotein in disease. Pharmacogenomics (2013) 0.91
The human paraoxonase-1 phenotype modifies the effect of statins on paraoxonase activity and lipid parameters. Br J Clin Pharmacol (2008) 0.90
Relationship between Paraoxonase 1 (PON1) gene polymorphisms and susceptibility of stroke: a meta-analysis. Eur J Epidemiol (2010) 0.90
Paraoxonase gene polymorphisms and haplotype analysis in a stroke population. BMC Med Genet (2006) 0.90
Dietary cholesterol increases paraoxonase 1 enzyme activity. J Lipid Res (2012) 0.88
Associations between high density lipoprotein mean particle size and serum paraoxonase-1 activity. J Res Med Sci (2012) 0.87
Additional Common Polymorphisms in the PON Gene Cluster Predict PON1 Activity but Not Vascular Disease. J Lipids (2012) 0.87
HDL-3 is a superior predictor of carotid artery disease in a case-control cohort of 1725 participants. J Am Heart Assoc (2014) 0.87
Genetic and nongenetic sources of variation in phospholipid transfer protein activity. J Lipid Res (2009) 0.87
Inflammation, infection, cancer and all that…the role of paraoxonases. Adv Exp Med Biol (2014) 0.86
Human paraoxonase-1 (PON1): Gene structure and expression, promiscuous activities and multiple physiological roles. Gene (2015) 0.83
Novel common and rare genetic determinants of paraoxonase activity: FTO, SERPINA12, and ITGAL. J Lipid Res (2012) 0.83
The role of paraoxonase (PON) enzyme in the extent and severity of the coronary artery disease in type-2 diabetic patients. Heart Vessels (2007) 0.83
Relationship of human paraoxonase-1 serum activity and genotype with atherosclerosis in individuals from the Deep South. Pharmacogenet Genomics (2011) 0.83
PLTP activity inversely correlates with CAAD: effects of PON1 enzyme activity and genetic variants on PLTP activity. J Lipid Res (2015) 0.81
No influence of increased intake of orange and blackcurrant juices and dietary amounts of vitamin E on paraoxonase-1 activity in patients with peripheral arterial disease. Eur J Nutr (2007) 0.81
Total serum oxidant/antioxidant status and arylesterase activity in recurrent aphthous stomatitis. Ann Dermatol (2013) 0.81
PON3 knockout mice are susceptible to obesity, gallstone formation, and atherosclerosis. FASEB J (2014) 0.80
Associations of PON1 and genetic ancestry with obesity in early childhood. PLoS One (2013) 0.80
Engineering human PON1 in an E. coli expression system. Adv Exp Med Biol (2010) 0.80
Rare coding variation in paraoxonase-1 is associated with ischemic stroke in the NHLBI Exome Sequencing Project. J Lipid Res (2014) 0.80
Recent progress in the genetics and epigenetics of paraoxonase: why it is relevant to children's environmental health. Curr Opin Pediatr (2015) 0.79
Biomarkers of sensitivity and exposure in Washington state pesticide handlers. Adv Exp Med Biol (2010) 0.79
Zinc-gene interaction related to inflammatory/immune response in ageing. Genes Nutr (2008) 0.79
Dietary fatty acid intake is associated with paraoxonase 1 activity in a cohort-based analysis of 1,548 subjects. Lipids Health Dis (2013) 0.79
Association between PON1 rs662 polymorphism and coronary artery disease. Eur J Clin Nutr (2014) 0.79
Serum paraoxonase activity is associated with variants in the PON gene cluster and risk of Alzheimer disease. Neurobiol Aging (2010) 0.79
Paraoxonase 1 activities and polymorphisms in autism spectrum disorders. J Cell Mol Med (2009) 0.79
Cholesterol efflux capacity, macrophage reverse cholesterol transport and cardioprotective HDL. Curr Opin Lipidol (2015) 0.78
The determination of Q192R polymorphism of paraoxonase 1 by using non-toxic substrate p-nitrophenylacetate. Indian J Hum Genet (2013) 0.78
A study of antioxidant activity in patients with schizophrenia taking atypical antipsychotics. Psychopharmacology (Berl) (2014) 0.78
Increased Levels of Human Carotid Lesion Linoleic Acid Hydroperoxide in Symptomatic and Asymptomatic Patients Is Inversely Correlated with Serum HDL and Paraoxonase 1 Activity. J Lipids (2012) 0.78
Serum Paraoxonase (PON1) Activity in North-West Indian Punjabi's with Acute Myocardial Infarction. Indian J Clin Biochem (2012) 0.78
PON1 status evaluation in patients with chronic arterial occlusion of lower limbs due to atherosclerosis obliterans. Arch Med Sci (2014) 0.78
Effects of dietary components on high-density lipoprotein measures in a cohort of 1,566 participants. Nutr Metab (Lond) (2014) 0.77
Paraoxonase 1 (PON1) C/T-108 association with longitudinal mean arterial blood pressure. Am J Hypertens (2012) 0.77
Addressing the link between paraoxonase-1 gene variants and the incidence of early onset myocardial infarction. Arch Med Sci (2015) 0.76
Paraoxonases-1, -2 and -3: What are their functions? Chem Biol Interact (2016) 0.76
Association between Paraoxonase 1 (PON1) Polymorphisms and the Risk of Acute Coronary Syndrome in a North African Population. PLoS One (2015) 0.75
Impact of antibacterial drugs on human serum paraoxonase-1 (hPON1) activity: an in vitro study. Asian Pac J Trop Biomed (2014) 0.75
Profile of the Paraoxonase 1 (PON1) Gene 192Q/R Polymorphism and Clinical Associations among Older Singaporean Chinese with Alzheimer's and Mixed Dementia. Dement Geriatr Cogn Dis Extra (2016) 0.75
Paraoxonase-1 and Early-Life Environmental Exposures. Ann Glob Health (2016) 0.75
Concentration of Smaller High-Density Lipoprotein Particle (HDL-P) Is Inversely Correlated With Carotid Intima Media Thickening After Confounder Adjustment: The Multi Ethnic Study of Atherosclerosis (MESA). J Am Heart Assoc (2016) 0.75
Effect of Resveratrol and Nicotine on PON1 Gene Expression: In Vitro Study. Indian J Clin Biochem (2013) 0.75
Individuals with autism have higher 8-Iso-PGF2α levels than controls, but no correlation with quantitative assay of Paraoxonase 1 serum levels. Metab Brain Dis (2017) 0.75
Paraoxonase (PON1) activity in patients with subclinical thoracic aortic atherosclerosis. Int J Cardiovasc Imaging (2014) 0.75
Positional cloning of the Werner's syndrome gene. Science (1996) 10.98
Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. Nat Genet (2013) 9.46
Tau is a candidate gene for chromosome 17 frontotemporal dementia. Ann Neurol (1998) 5.42
CSF tau/Abeta42 ratio for increased risk of mild cognitive impairment: a follow-up study. Neurology (2007) 4.24
Mutation-specific functional impairments in distinct tau isoforms of hereditary FTDP-17. Science (1998) 4.07
Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature (1998) 3.84
In vivo accuracy of multispectral magnetic resonance imaging for identifying lipid-rich necrotic cores and intraplaque hemorrhage in advanced human carotid plaques. Circulation (2001) 3.47
Quantitative evaluation of carotid plaque composition by in vivo MRI. Arterioscler Thromb Vasc Biol (2004) 3.37
A familial Alzheimer's disease locus on chromosome 1. Science (1995) 3.14
Genetic linkage evidence for a familial Alzheimer's disease locus on chromosome 14. Science (1992) 3.14
The molecular basis of the human serum paraoxonase activity polymorphism. Nat Genet (1993) 2.88
Statin therapy and risk of dementia in the elderly: a community-based prospective cohort study. Neurology (2004) 2.83
Cerebrospinal fluid and plasma insulin levels in Alzheimer's disease: relationship to severity of dementia and apolipoprotein E genotype. Neurology (1998) 2.61
The effect of the human serum paraoxonase polymorphism is reversed with diazoxon, soman and sarin. Nat Genet (1996) 2.57
Missense and silent tau gene mutations cause frontotemporal dementia with parkinsonism-chromosome 17 type, by affecting multiple alternative RNA splicing regulatory elements. Proc Natl Acad Sci U S A (1999) 2.26
The number of trait loci in late-onset Alzheimer disease. Am J Hum Genet (2000) 2.24
Effects of intranasal insulin on cognition in memory-impaired older adults: modulation by APOE genotype. Neurobiol Aging (2005) 2.15
Effects of prolonged intensive lipid-lowering therapy on the characteristics of carotid atherosclerotic plaques in vivo by MRI: a case-control study. Arterioscler Thromb Vasc Biol (2001) 2.14
Association of an apolipoprotein CII allele with familial dementia of the Alzheimer type. J Neurogenet (1987) 2.12
Purification of a leucine-specific binding protein from Escherichia coli. Biochem Biophys Res Commun (1970) 2.09
Increased platelet membrane fluidity as a diagnostic marker for Alzheimer's disease: a test in population-based cases and controls. Neurology (1992) 2.08
Using census data and birth certificates to reconstruct the early-life socioeconomic environment and the relation to the development of Alzheimer's disease. Epidemiology (2001) 1.96
Determination of paraoxonase (PON1) status requires more than genotyping. Pharmacogenetics (1999) 1.88
Head circumference and incident Alzheimer's disease: modification by apolipoprotein E. Neurology (2001) 1.88
Alzheimer's disease, apolipoprotein E4, and gender. JAMA (1994) 1.86
Effects of 5' regulatory-region polymorphisms on paraoxonase-gene (PON1) expression. Am J Hum Genet (2001) 1.85
Xylose isomerase from Escherichia coli. Characterization of the protein and the structural gene. J Biol Chem (1984) 1.82
Catalytic efficiency determines the in-vivo efficacy of PON1 for detoxifying organophosphorus compounds. Pharmacogenetics (2000) 1.79
Increased CSF cortisol in AD is a function of APOE genotype. Neurology (2001) 1.78
Serum cholesterol and risk of Alzheimer disease: a community-based cohort study. Neurology (2005) 1.75
Binding assays for amino acids. The utilization of a cystine binding protein from Escherichia coli for the determination of acid-soluble cystine in small physiological samples. J Biol Chem (1974) 1.74
Measurement of atherosclerotic carotid plaque size in vivo using high resolution magnetic resonance imaging. Circulation (1998) 1.74
Biosynthesis of bacterial glycogen. Primary structure of Escherichia coli ADP-glucose synthetase as deduced from the nucleotide sequence of the glg C gene. J Biol Chem (1983) 1.73
Impaired olfaction as a marker for cognitive decline: interaction with apolipoprotein E epsilon4 status. Neurology (1999) 1.72
Renaturation and identification of periplasmic proteins in two-dimensional gels of Escherichia coli. J Biol Chem (1982) 1.69
Resolution of the multiplicity of the glutamate and aspartate transport systems of Escherichia coli. J Biol Chem (1977) 1.65
Physical and functional interaction between p53 and the Werner's syndrome protein. J Biol Chem (1999) 1.64
Autism and the serotonin transporter: the long and short of it. Mol Psychiatry (2005) 1.62
Purification and properties of a ribose-binding protein from Escherichia coli. J Biol Chem (1974) 1.62
A multichamber equilibrium dialysis apparatus. Anal Biochem (1972) 1.61
Impaired dopaminergic neurotransmission and microtubule-associated protein tau alterations in human LRRK2 transgenic mice. Neurobiol Dis (2010) 1.60
MR imaging of adventitial vasa vasorum in carotid atherosclerosis. Magn Reson Med (2008) 1.57
Interactions of apolipoprotein E genotype, total cholesterol level, age, and sex in prediction of Alzheimer's disease: a case-control study. Neurology (1995) 1.55
Gender difference in apolipoprotein E-associated risk for familial Alzheimer disease: a possible clue to the higher incidence of Alzheimer disease in women. Am J Hum Genet (1996) 1.54
A mutation in the microtubule-associated protein tau in pallido-nigro-luysian degeneration. Neurology (1999) 1.52
Mutations in the consensus helicase domains of the Werner syndrome gene. Werner's Syndrome Collaborative Group. Am J Hum Genet (1997) 1.52
Regulation of Glutamine Transport in Escherichia coli. J Bacteriol (1975) 1.51
Cycad exposure and risk of dementia, MCI, and PDC in the Chamorro population of Guam. Neurology (2007) 1.48
Familial Alzheimer's disease in American descendants of the Volga Germans: probable genetic founder effect. Ann Neurol (1988) 1.47
Polymorphisms in the human paraoxonase (PON1) promoter. Pharmacogenetics (2001) 1.46
Characterization of cDNA clones encoding rabbit and human serum paraoxonase: the mature protein retains its signal sequence. Biochemistry (1991) 1.46
High-density SNP association study and copy number variation analysis of the AUTS1 and AUTS5 loci implicate the IMMP2L-DOCK4 gene region in autism susceptibility. Mol Psychiatry (2009) 1.45
Telepathology and the networking of pathology diagnostic services. Arch Pathol Lab Med (1987) 1.43
Head injury and risk of Alzheimer's disease by apolipoprotein E genotype. Am J Epidemiol (1997) 1.42
Spectrophotometric assays for the enzymatic hydrolysis of the active metabolites of chlorpyrifos and parathion by plasma paraoxonase/arylesterase. Anal Biochem (1989) 1.42
A novel progranulin mutation associated with variable clinical presentation and tau, TDP43 and alpha-synuclein pathology. Brain (2007) 1.40
p53-mediated apoptosis is attenuated in Werner syndrome cells. Genes Dev (1999) 1.39
Role of genetic polymorphism of human plasma paraoxonase/arylesterase in hydrolysis of the insecticide metabolites chlorpyrifos oxon and paraoxon. Am J Hum Genet (1988) 1.38
A comparison of three methods for detecting KRAS mutations in formalin-fixed colorectal cancer specimens. Br J Cancer (2012) 1.35
A binding protein for L-glutamine and its relation to active transport in E. coli. Arch Biochem Biophys (1971) 1.35
Expression of the Escherichia coli xylose isomerase gene in Saccharomyces cerevisiae. Appl Environ Microbiol (1987) 1.35
Serum paraoxonase and its influence on paraoxon and chlorpyrifos-oxon toxicity in rats. Toxicol Appl Pharmacol (1990) 1.32
Toward localization of the Werner syndrome gene by linkage disequilibrium and ancestral haplotyping: lessons learned from analysis of 35 chromosome 8p11.1-21.1 markers. Am J Hum Genet (1996) 1.31
Apolipoprotein E genotype and Alzheimer's disease. Lancet (1993) 1.30
A prion protein variant in a family with the telencephalic form of Gerstmann-Sträussler-Scheinker syndrome. Neurology (1991) 1.29
Plasma paraoxonase polymorphism: a new enzyme assay, population, family, biochemical, and linkage studies. Am J Hum Genet (1983) 1.27
Differentiation of intraplaque versus juxtaluminal hemorrhage/thrombus in advanced human carotid atherosclerotic lesions by in vivo magnetic resonance imaging. Circulation (2004) 1.27
The role of paraoxonase (PON1) in the detoxication of organophosphates and its human polymorphism. Chem Biol Interact (1999) 1.26
Apolipoprotein J is associated with paraoxonase in human plasma. Biochemistry (1994) 1.24
The amino acid sequence of D-ribose-binding protein from Escherichia coli K12. J Biol Chem (1983) 1.24
Midlife cardiovascular risk factors, ApoE, and cognitive decline in elderly male twins. Neurology (1998) 1.24
A clinical pathological comparison of three families with frontotemporal dementia and identical mutations in the tau gene (P301L) Brain (1999) 1.22
Paraoxonase protects against chlorpyrifos toxicity in mice. Toxicol Lett (1995) 1.22
Purification of rabbit and human serum paraoxonase. Biochemistry (1991) 1.21
Evidence for an interaction between apolipoprotein E genotype, gender, and Alzheimer disease. Alzheimer Dis Assoc Disord (2000) 1.21
Homozygous and compound heterozygous mutations at the Werner syndrome locus. Hum Mol Genet (1996) 1.19
Telepathology. Long-distance diagnosis. Am J Clin Pathol (1989) 1.18
Paraoxon hydrolysis in human serum mediated by a genetically variable arylesterase and albumin. Am J Hum Genet (1984) 1.17
Cloning, sequencing, and mapping of the human chromosome 14 heat shock protein gene (HSPA2). Genomics (1994) 1.16
Determinants of 4-repeat tau expression. Coordination between enhancing and inhibitory splicing sequences for exon 10 inclusion. J Biol Chem (2000) 1.16
The role of ribose-binding protein in transport and chemotaxis in Escherichia coli K12. Arch Biochem Biophys (1977) 1.14
Human and rabbit paraoxonases: purification, cloning, sequencing, mapping and role of polymorphism in organophosphate detoxification. Chem Biol Interact (1993) 1.14
A simple preparative polyacrylamide disc gel electrophoresis apparatus: purification of three branched-chain amino acid binding proteins from Escherichia coli. Anal Biochem (1973) 1.13
Evidence that the apolipoprotein E-genotype effects on lipid levels can change with age in males: a longitudinal analysis. Am J Hum Genet (1997) 1.11
A genomic sequence analysis of the mouse and human microtubule-associated protein tau. Mamm Genome (2001) 1.11
Chromosome 17 and hereditary dementia: linkage studies in three non-Alzheimer families and kindreds with late-onset FAD. Neurology (1997) 1.10
Yeast as a model system to study drugs effective against apicomplexan proteins. Methods (1997) 1.10
Serum paraoxonase status: a major factor in determining resistance to organophosphates. J Toxicol Environ Health (1993) 1.10
A distinct familial presenile dementia with a novel missense mutation in the tau gene. Neuroreport (1999) 1.10